NCT05318833已完成1 期
A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS7415 Tablets in Patients With Advanced Malignant Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity (DLT)
研究概览
简要总结
This study is a multicenter, open phase I clinical study of dose escalation and dose extension of HRS7415 in subjects with advanced malignant tumors. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS7415 tablets.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects volunteered to participate in the clinical study, understood the study procedure and was able to sign informed consent in person.
- •18 to 75 years old, male or female.
- •ECOG Performance Status of 0 or
- •The estimated survival time is ≥12 weeks.
- •Subjects with advanced or metastatic malignancy confirmed by histopathology or cytology.
- •Solid tumor subjects had measurable lesions that met RECIST 1.1 criteria.
- •Adequate hematology and terminal organ function, with vital organ function meeting the upper and lower limits required by the protocol.
- •Male subjects and fertile female subjects must agree to use medically approved contraception during the study period and for 6 months following the study; Fertile female subjects must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to initial dosing and must be non-lactation blood pregnancy test must be negative and not lactation.
排除标准
- •Subjects plan to receive any other antitumor therapy during the study period.
- •Subjects received chemotherapy, radiotherapy, biotherapy, targeted therapy, or immunotherapy within 4 weeks prior to initial dosing.
- •Major surgery other than diagnosis or biopsy was performed within 4 weeks prior to initial dosing.
- •Received any other investigational drug or treatment that is not on the market within 4 weeks prior to initial dosing.
- •The damage caused by any previous antineoplastic therapy has not recovered to grade ≤
- •Imaging diagnosis showed tumor lesion or meningeal metastasis in the brain.
- •Active heart disease in the 6 months prior to initial dosing.
- •Had other malignancies within 5 years prior to first dosing.
- •Subjects with poorly controlled hypertension and a previous history of hypertensive crisis or hypertensive encephalopathy.
- •Having one of several factors affecting oral medication or having active gastrointestinal disease or other medical conditions that may result in significant influence on drug absorption, distribution, metabolism or excretion;
- •Active hepatitis B and C;
- •Serious infections that require intravenous antibiotics, antivirals or antifungals to control;
- •History of immune deficiency or organ transplantation;
- •Comorbidities or any other conditions that, in the investigator's judgment, seriously endanger patient safety or prevent patients from completing the study.
研究组 & 干预措施
HRS7415
Experimental
干预措施: HRS7415 (Drug)
结局指标
主要结局
Dose-limiting toxicity (DLT)
时间窗: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
Phase II recommended dose (RP2D)
时间窗: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
maximum tolerated dose (MTD)
时间窗: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months
次要结局
- Single dose parameters: Area under the time curve from 0 to infinity (AUC0-inf) of HRS7415 and its main metabolite after single dosing (if applicable)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Incidence, severity, duration, and association of adverse events (AE) and severe adverse events (SAE) with the study drug, in addition to abnormalities in vital signs, electrocardiogram, and laboratory tests(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Single dose parameters: Area under the curve from 0 to the last measurable concentration time point t (AUC0-t) of HRS7415 and its main metabolite after single dosing (if applicable)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Single dose parameters: Half-value period (t1/2) of HRS7415 and its main metabolite after single dosing (if applicable)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Single dose parameters: Apparent clearance (CL/F) of HRS7415 and its main metabolite after single dosing (if applicable)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Multiple dose parameters: Steady state peak concentration (Cmax，ss) of HRS7415 and its main metabolite after multiple dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Multiple dose parameters: Time to peak (Tmax, ss) of HRS7415 and its main metabolite after multiple dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Efficacy endpoints: Disease control rate (DCR)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Single dose parameters: Peak plasma concentration (Cmax) of HRS7415 and its main metabolite after single dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Single dose parameters: Time to peak (Tmax) of HRS7415 and its main metabolite after single dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 year)
- Single dose parameters: Apparent volume of distribution (Vz/F) of HRS7415 and its main metabolite after single dosing (if applicable)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Multiple dose parameters: Steady valley concentration (Cmin，ss) of HRS7415 and its main metabolite after multiple dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Multiple dose parameters: Area under steady-state drug concentration-time curve (AUCss) of HRS7415 and its main metabolite after multiple dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Efficacy endpoints: Objective response rate (ORR)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Efficacy endpoints: Duration of response (DoR)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Efficacy endpoints: Progression-free survival (PFS)(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
- Multiple dose parameters: Drug storage ratio (Rac) of HRS7415 and its main metabolite after multiple dosing(From the beginning of first patient in (FPI) to the end of study up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant TumourAdvanced Malignant TumourNCT06383871Shandong Suncadia Medicine Co., Ltd.233
Unknown
1 期
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid TumorAdvanced Solid TumorGastric Cancer (GC)Gastroesophageal Junction (GEJ) CancerPancreatic CancerNCT05009966CSPC ZhongQi Pharmaceutical Technology Co., Ltd.272
已完成
1 期
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid TumorAdvanced Malignant Solid TumorsNCT05383703Moon (Guangzhou) Biotechnology Co., Ltd.12
已完成
1 期
Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy VolunteersInterstitial Lung DiseaseNCT04415671AdAlta Limited50
招募中
1 期
Phase I Study of KN044 in Locally Advanced/Metastatic Solid TumorsAdvanced Solid TumorsNCT04126590Changchun Intellicrown Pharmaceutical Co. LTD39